Investors Are Craving More from Agile Therapeutics Inc. [AGRX] Stocks: Here is Why

Agile Therapeutics Inc. [AGRX] has traded in a range of $1.35 to $4.77 in the last 1 year. As of this writing, the stock is at $2.99, up 3.82%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, AGRX shares are 3.60% up with the monthly amount drift of -2.37% and seems bad in a long time frame.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 30, November 2020, Agile Therapeutics Announces Peer-Reviewed Publication of Phase 3 SECURE Study Results for Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System in Contraception. According to news published on Yahoo Finance, Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Contraception, an international, peer-reviewed, reproductive health journal, published the primary safety, efficacy, and tolerability results from the Phase 3 SECURE study evaluating Twirla® (levonorgestrel and ethinyl estradiol) transdermal system. The results have been published online in Contraception ( and will also appear in a future print edition of the journal.

Analyst Birdseye View:

The most recent analyst activity for Agile Therapeutics Inc. [NASDAQ:AGRX] stock was on November 29, 2018, when it was Initiated with a Buy rating from Maxim Group, which also raised its 12-month price target on the stock to $3. Before that, on April 12, 2019, Janney Recapitulated a Buy rating and elevated its amount target to $4. On December 26, 2017, William Blair Downgrade a Mkt perform rating. On December 26, 2017, Janney Downgrade a Neutral rating. On October 02, 2017, H.C. Wainwright Resumed a Buy rating and increased its price target to $10. On September 14, 2017, RBC Capital Mkts Reiterated an Outperform rating and boosted its amount target on this stock to $10. On July 19, 2017, H.C. Wainwright Initiated a Buy rating and boosted its target amount on this stock to $10.

In the past 52 weeks of trading, this stock has oscillated between a low of $1.35 and a peak of $4.77. Right now, the middling Wall Street analyst 12-month amount mark is $8.00. At the most recent market close, shares of Agile Therapeutics Inc. [NASDAQ:AGRX] were valued at $2.99.


If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 0.37 and the whole liability to whole assets at 0.35.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 2.81 points at 1st support level, the second support level is making up to 2.73. But as of 1st resistance point, this stock is sitting at 2.93 and at 2.97 for 2nd resistance point.

Agile Therapeutics Inc. [AGRX] reported its earnings at -$0.18 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.18/share signifying the difference of 0 and 0.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.12 calling estimates for -$0.14/share with the difference of 0.02 depicting the surprise of 14.30%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Agile Therapeutics Inc. [NASDAQ:AGRX] is 10.20. Likewise, the Quick ratio is also the same, showing Cash ratio at 9.09. Now if looking for a valuation of this stock’s amount to book ratio is 3.82.

Insider Stories

The most recent insider trade was by Reilly Dennis, Chief Financial Officer, and it was the purchase of 9000.0 shares on Sep 28. PERCEPTIVE ADVISORS LLC, the 10% Owner, completed a purchase of 1.0 million shares on Mar 13. On Mar 04, Reilly Dennis, Chief Financial Officer, completed a purchase of 25000.0 shares.